Skip to main content

Table 2 Patient characteristic

From: Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial

Patient characteristics

Placebo

Cocculine

All patients

p

Total

217

214

431

 

Age, years

   

0.56*

Median (min-max)

52.8 (20–74)

53.3 (30–74)

52.8 (20–74)

 

Delay from surgery (days)

    

Median (min-max)

27.50 (4.00–70.0)

27.0 (1.0–72.0)

27.0 (1.0–72.0)

0.90*

ECOG Performance Status

n = 197

n = 198

n = 395

0.64†

 0, n (%)

177 (89.8)

175 (88.4)

352 (89.1)

 

 1, n (%)

20 (10.2)

23 (11.6)

43 (10.9)

 

Nausea and vomiting susceptibility

n = 188

n = 189

n = 377

0.47†

Yes n (%)

63 (33.5)

70 (37.0)

133 (35.3)

 

pT grade

n = 215

n = 211

n = 426

1.00††

 T1 a-b-c, n(%)

119 (55.3)

118 (55.9)

237 (55.6)

 

 T2, n(%)

87 (40.5)

85 (40.3)

172 (40.4)

 

 T3, n(%)

7 (3.3)

7 (3.3)

14 (3.3)

 

 T4, n(%)

2 (0.9)

1 (0.5)

3 (0.7)

 

pN grade

n = 213

n = 213

n = 426

0.84†

 N-, n(%)

85 (39.9)

83 (39.0)

168 (39.4)

 

 N+, n(%)

128 (60.1)

130 (61.0)

258 (60.6)

 
  1. *: Mann–Whitney U test; † : Person’s chi-square test; †† : Fischer test.